Join
Live feed
·
PRReleasevia Quantisnow
ALX Oncology Holdings Inc. logo

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ALXO· ALX Oncology Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALXO (ALX Oncology Holdings Inc.) and more on Quantisnow.

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer | Quantisnow